Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, September 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 116 articles:
HTML format


 

Single Articles

  1. YANG X, Shi L, Yi C, Yang Y, et al
    MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1.
    Am J Cancer Res. 2017;7:1738-1753.
    Abstract    

    Abstract available

  2. KUS T, Aktas G
    Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival.
    Turk J Urol. 2017;43:273-278.
    Abstract    

    Abstract available

  3. SUN M, Zhao W, Zeng Y, Zhang D, et al
    Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target.
    Onco Targets Ther. 2017;10:3949-3956.
    Abstract    

    Abstract available

  4. CHENG B, Qiu X, Li H, Yang G, et al
    The safety and efficacy of front-firing green-light laser endoscopic en bloc photoselective vapo-enucleation of non-muscle-invasive bladder cancer.
    Ther Clin Risk Manag. 2017;13:983-988.
    Abstract    

    Abstract available

  5. BOUSTANI J, Bertaut A, Galsky MD, Rosenberg JE, et al
    Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Acta Oncol. 2017 Aug 30:1-7. doi: 10.1080/0284186X.2017.1369565.
    Abstract    

    Abstract available

  6. VERMA N, Pink M, Boland S, Rettenmeier AW, et al
    Benzo[a]pyrene-induced metabolic shift from glycolysis to pentose phosphate pathway in the human bladder cancer cell line RT4.
    Sci Rep. 2017;7:9773.
    Abstract    

    Abstract available

  7. JIN F, Thaiparambil J, Donepudi SR, Vantaku VR, et al
    Tobacco-specific carcinogens induce hypermethylation, DNA adducts and DNA damage in Bladder Cancer.
    Cancer Prev Res (Phila). 2017 Aug 29. pii: canprevres.0198.2017.
    Abstract    

    Abstract available

  8. ABUFARAJ M, Haitel A, Moschini M, Gust K, et al
    Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Aug 15. pii: S1558-7673(17)30198.
    Abstract    

    Abstract available

  9. WOJTCZYK-MIASKOWSKA A, Presler M, Michajlowski J, Matuszewski M, et al
    Gene Expression, DNA Methylation and Prognostic Significance of DNA Repair Genes in Human Bladder Cancer.
    Cell Physiol Biochem. 2017;42:2404-2417.
    Abstract    

    Abstract available

  10. HUANG H, Jin H, Zhao H, Wang J, et al
    RhoGDIbeta Promotes Sp1/MMP-2 Expression and Bladder Cancer Invasion Through Perturbing miR-200c-Targeted JNK2 Protein Translation.
    Mol Oncol. 2017 Aug 28. doi: 10.1002/1878-0261.12132.
    Abstract    

    Abstract available

  11. LORAN OB, Sinyakova LA, Gundorova LV, Kosov VA, et al
    [High oncogenic risk human papillomavirus and urinary bladder cancer].
    Urologiia. 2017;:60-66.
    Abstract    

    Abstract available

  12. PARKER WP, Smelser W, Lee EK, Habermann EB, et al
    Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients.
    Clin Genitourin Cancer. 2017 Aug 1. pii: S1558-7673(17)30208.
    Abstract    

    Abstract available

  13. HE X, Ding X, Wen D, Hou J, et al
    Exploration of the pathways and interaction network involved in bladder cancer cell line with knockdown of Opa interacting protein 5.
    Pathol Res Pract. 2017 Aug 1. pii: S0344-0338(17)30130.
    Abstract    

    Abstract available

  14. ABDEL-RAHMAN O
    Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts.
    Clin Genitourin Cancer. 2017 Aug 3. pii: S1558-7673(17)30235.
    Abstract    

    Abstract available

  15. KUHN C, Lehmann ML, Kress A, Truss MC, et al
    Micro-brushing-based technique to gain fresh urothelial cells for gene expression analysis.
    J Toxicol Environ Health A. 2017;80.
    Abstract    

    Abstract available

  16. LEE CH, Tan CH, Faria SC, Kundra V, et al
    Role of Imaging in the Local Staging of Urothelial Carcinoma of the Bladder.
    AJR Am J Roentgenol. 2017 Feb 22:1-13. doi: 10.2214/AJR.16.17114.
    Abstract    

    Abstract available

  17. GOTTLIEB J, Princenthal R, Cohen MI
    Multi-parametric MRI findings of granulomatous prostatitis developing after intravesical bacillus calmette-guerin therapy.
    Abdom Radiol (NY). 2017;42:1963-1967.
    Abstract    

    Abstract available

  18. PAN S, Smith AD, Motamedinia P
    Minimally Invasive Therapy for Upper Tract Urothelial Cell Cancer.
    J Endourol. 2017;31:238-245.
    Abstract    

    Abstract available

  19. SHAH TS, Kaag M, Raman JD, Chan W, et al
    Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
    Hum Pathol. 2017;61:90-96.
    Abstract    

    Abstract available

  20. YE JR, Liu L, Zheng F
    Long Noncoding RNA Bladder Cancer Associated Transcript 1 Promotes the Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer Through Sponging miR-144.
    DNA Cell Biol. 2017 Sep 8. doi: 10.1089/dna.2017.3854.
    Abstract    

    Abstract available

  21. ACHARYA AP, Theisen KM, Correa A, Meyyappan T, et al
    An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation.
    Adv Healthc Mater. 2017 Sep 8. doi: 10.1002/adhm.201700808.
    Abstract    

    Abstract available

  22. KATAFIGIOTIS I, Sfoungaristos S, Martini A, Stravodimos K, et al
    Bladder cancer to patients younger than 30 years: a retrospective study and review of the literature.
    Urologia. 2017 Sep 5:0. doi: 10.5301/uj.5000264.
    Abstract    

    Abstract available

  23. WHANG YM, Jin SB, Park SI, Chang IH, et al
    MEK inhibition enhances efficacy of bacillus Calmette-Guerin on bladder cancer cells by reducing release of Toll-like receptor 2-activated antimicrobial peptides.
    Oncotarget. 2017;8:53168-53179.
    Abstract    

    Abstract available

  24. WU J, Yu C, Cai L, Lu Y, et al
    Effects of increased Kindlin-2 expression in bladder cancer stromal fibroblasts.
    Oncotarget. 2017;8:50692-50703.
    Abstract    

    Abstract available

  25. ECKE TH, Stier K, Weickmann S, Zhao Z, et al
    miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
    Cancer Med. 2017 Sep 6. doi: 10.1002/cam4.1161.
    Abstract    

    Abstract available

  26. BROWNE C, Davis NF, Nolan WJ, MacCraith ED, et al
    Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy.
    Curr Urol. 2017;10:132-135.
    Abstract    

    Abstract available

  27. SCHROECK FR, Sirovich B, Seigne JD, Robertson DJ, et al
    Assembling and validating data from multiple sources to study care for Veterans with bladder cancer.
    BMC Urol. 2017;17:78.
    Abstract    

    Abstract available

  28. CLINTON T, Lotan Y
    Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.
    Rambam Maimonides Med J. 2017 Aug 22. doi: 10.5041/RMMJ.10314.
    Abstract    

    Abstract available

  29. VRIELING A
    Lifestyle and bladder cancer prevention: no consistent evidence from cohort studies.
    Eur J Epidemiol. 2017 Sep 4. doi: 10.1007/s10654-017-0306.
    Abstract    



  30. WANG D, Kong X, Li Y, Qian W, et al
    Curcumin inhibits bladder cancer stem cells by suppressing Sonic Hedgehog pathway.
    Biochem Biophys Res Commun. 2017 Sep 4. pii: S0006-291X(17)31732.
    Abstract    

    Abstract available

  31. MORENO-LONDONO AP, Bello-Alvarez C, Pedraza-Chaverri J
    Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line.
    Food Chem Toxicol. 2017 Sep 1. pii: S0278-6915(17)30506.
    Abstract    

    Abstract available

  32. XIONG Y, Wang L, Li Y, Chen M, et al
    The Long Non-Coding RNA XIST Interacted with MiR-124 to Modulate Bladder Cancer Growth, Invasion and Migration by Targeting Androgen Receptor (AR).
    Cell Physiol Biochem. 2017;43:405-418.
    Abstract    

    Abstract available

  33. KOLAWOLE OM, Lau WM, Mostafid H, Khutoryanskiy VV, et al
    Advances in intravesical drug delivery systems to treat bladder cancer.
    Int J Pharm. 2017 Aug 31. pii: S0378-5173(17)30834.
    Abstract    

    Abstract available

  34. LIEM EIML, Baard J, Cauberg ECC, Bus MTJ, et al
    Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
    Med Oncol. 2017;34:172.
    Abstract    

    Abstract available

  35. BAGRODIA A, Sukhu R, Winer AG, Levy E, et al
    Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30232.
    Abstract    

    Abstract available

  36. HADEN TD, Prunty MC, Jones AB, Deroche CB, et al
    Comparative Perioperative Outcomes in Septuagenarians and Octogenarians Undergoing Radical Cystectomy for Bladder Cancer-Do Outcomes Differ?
    Eur Urol Focus. 2017 Aug 30. pii: S2405-4569(17)30197.
    Abstract    

    Abstract available

  37. KATZ H, Wassie E, Alsharedi M
    Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Med Oncol. 2017;34:170.
    Abstract    

    Abstract available


  38. Local Delivery of IFNalpha Has Antitumor Activity in Bladder Cancer.
    Cancer Discov. 2017 Sep 1. doi: 10.1158/2159-8290.CD-RW2017.
    Abstract    

    Abstract available

  39. HUANG RF, He C, Zhu WF, Li Y, et al
    [Application of immunohistochemistry for p16 and GATA3 and molecular HPV typing in diagnosis of secondary bladder involvement by cervical carcinoma].
    Zhonghua Bing Li Xue Za Zhi. 2017;46:388-392.
    Abstract    

    Abstract available

  40. SLUSSER-NORE A, Garrett SH, Zhou XD, Sens DA, et al
    The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.
    Toxicol Appl Pharmacol. 2017;331:41-53.
    Abstract    

    Abstract available

  41. NARANG SK, Alam NN, Campain NJ, Pathak S, et al
    Parastomal hernia following cystectomy and ileal conduit urinary diversion: a systematic review.
    Hernia. 2017;21:163-175.
    Abstract    

    Abstract available

  42. OWEIDA A, Bhatia S, Hirsch K, Calame D, et al
    Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.
    Mol Carcinog. 2017;56:1189-1196.
    Abstract    

    Abstract available

  43. GORDETSKY J, Collingwood R, Lai WS, Del Carmen Rodriquez Pena M, et al
    Second Opinion Expert Pathology Review in Bladder Cancer: Implications for Patient Care.
    Int J Surg Pathol. 2017 Sep 1:1066896917730903. doi: 10.1177/1066896917730903.
    Abstract    

    Abstract available

  44. LIU Q, Liao B, Tian Y, Chen Y, et al
    Total fluid consumption and risk of bladder cancer: a meta-analysis with updated data.
    Oncotarget. 2017;8:55467-55477.
    Abstract    

    Abstract available

  45. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guerin (BCG) and to oxidative damage.
    Oncotarget. 2017;8:54506-54517.
    Abstract    

    Abstract available

  46. VETTERLEIN MW, Seisen T, Leow JJ, Preston MA, et al
    Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer.
    Clin Genitourin Cancer. 2017 Aug 24. pii: S1558-7673(17)30248.
    Abstract    

    Abstract available

  47. JUNG JH, Gudeloglu A, Kiziloz H, Kuntz GM, et al
    Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Cochrane Database Syst Rev. 2017;9:CD011864.
    Abstract    

    Abstract available

  48. SIDAWAY P
    Bladder cancer: IFNalpha-2b gene transfer: a new approach for BCG-resistant disease.
    Nat Rev Urol. 2017 Sep 12. doi: 10.1038/nrurol.2017.
    Abstract    



  49. MOSCHINI M, D'Andrea D, Korn S, Irmak Y, et al
    Characteristics and clinical significance of histological variants of bladder cancer.
    Nat Rev Urol. 2017 Sep 12. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  50. LIANG Z, Zhang Q, Wang C, Shi F, et al
    Hyaluronic acid/ Hyaluronidase as biomarkers for bladder cancer: a diagnostic meta-analysis.
    Neoplasma. 2017 Sep 12. doi: 10.4149/neo_2017.
    Abstract    

    Abstract available

  51. YANG L, Xue Y, Liu J, Zhuang J, et al
    Long noncoding RNA ASAP1-IT1 promotes cancer stemness and predicts a poor prognosis in patients with bladder cancer.
    Neoplasma. 2017 Sep 12. doi: 10.4149/neo_2017.
    Abstract    

    Abstract available

  52. SZYMANSKA B, Dlugosz A
    The role of the BLCA-4 nuclear matrix protein in bladder cancer.
    Postepy Hig Med Dosw (Online). 2017;71:681-689.
    Abstract    

    Abstract available

  53. SHEN J, Zhang J, Xiao M, Yang J, et al
    MiR-203 Suppresses Bladder Cancer Cell Growth and Targets the Twist1.
    Oncol Res. 2017 Sep 6. doi: 10.3727/096504017X15041934685237.
    Abstract    

    Abstract available

  54. IMAOKA Y, Kuranishi F, Miyazaki T, Yasuda H, et al
    Long-lasting complete response status of advanced stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine: two case reports.
    World J Surg Oncol. 2017;15:170.
    Abstract    

    Abstract available

  55. GANJI SM, Saidijam M, Amini R, Mousavi-Bahar SH, et al
    Evaluation of MicroRNA-99a and MicroRNA-205 Expression Levels in Bladder Cancer.
    Int J Mol Cell Med. 2017;6:87-95.
    Abstract    

    Abstract available

  56. SATHE A, Nawroth R
    Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
    Methods Mol Biol. 2018;1655:335-350.
    Abstract    

    Abstract available

  57. BERNARDO C, Santos LL
    Patient-Derived Bladder Cancer Xenografts.
    Methods Mol Biol. 2018;1655:169-175.
    Abstract    

    Abstract available

  58. OLIVEIRA PA, Vasconcelos-Nobrega C, Gil da Costa RM, Arantes-Rodrigues R, et al
    The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.
    Methods Mol Biol. 2018;1655:155-167.
    Abstract    

    Abstract available

  59. TOMMASI S, Besaratinia A
    A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer.
    Methods Mol Biol. 2018;1655:29-41.
    Abstract    

    Abstract available

  60. UHLIG A, Strauss A, Seif Amir Hosseini A, Lotz J, et al
    Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2017 Sep 6. pii: S2405-4569(17)30199.
    Abstract    

    Abstract available

  61. ZHANG Q, Zhang S, Zhang S, Wang W, et al
    Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients.
    BMC Urol. 2017;17:81.
    Abstract    

    Abstract available

  62. RINGUETTE GOULET C, Bernard G, Chabaud S, Couture A, et al
    Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery.
    Biomaterials. 2017;145:233-241.
    Abstract    

    Abstract available

  63. NI W, Li M, Cui J, Xing Z, et al
    808nm light triggered black TiO2 nanoparticles for killing of bladder cancer cells.
    Mater Sci Eng C Mater Biol Appl. 2017;81:252-260.
    Abstract    

    Abstract available

  64. MOSCHINI M, Shariat SF, Abufaraj M, Foerster B, et al
    Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy.
    Urol Oncol. 2017 Sep 5. pii: S1078-1439(17)30423.
    Abstract    

    Abstract available

  65. LIANG L, Zhou N, Xu H, Liu D, et al
    Urachal mucinous adenocarcinoma with pseudomyxoma peritonei: A case report.
    Medicine (Baltimore). 2017;96:e7548.
    Abstract    

    Abstract available

  66. INOUE S, Mizushima T, Fujita K, Meliti A, et al
    GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Hum Pathol. 2017;64:83-90.
    Abstract    

    Abstract available

  67. FURUDOI A, Varinot J, Phe V, Roupret M, et al
    Urothelial carcinoma in first histological diagnosis of patients over 80 years has distinctive histological features: a retrospective single-institution study of 185 patients.
    Virchows Arch. 2017;470:561-565.
    Abstract    

    Abstract available

  68. SWERDLOW AJ, Cooke R, Beckers D, Borgstrom B, et al
    Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.
    J Clin Endocrinol Metab. 2017;102:1661-1672.
    Abstract    

    Abstract available

  69. TAN WS, Lamb BW, Khetrapal P, Tan MY, et al
    Blood Transfusion Requirement and Not Preoperative Anemia Are Associated with Perioperative Complications Following Intracorporeal Robot-Assisted Radical Cystectomy.
    J Endourol. 2017;31:141-148.
    Abstract    

    Abstract available

  70. SUMA TL, Ramanathan S, Padma M, Appaji L, et al
    A Case of Urachal Yolk Sac Tumor With Spontaneous Rupture in a Child.
    J Pediatr Hematol Oncol. 2017;39:e82-e84.
    Abstract    

    Abstract available

  71. WESSELIUS A, Zeegers M
    Re: Lifestyle and bladder cancer prevention: no consistent evidence from cohort studies.
    Eur J Epidemiol. 2017 Sep 19. doi: 10.1007/s10654-017-0307.
    Abstract    



  72. SZYMANSKA B, Sawicka E, Guzik A, Zdrojowy R, et al
    The Diagnostic Value of Nuclear Matrix Proteins in Bladder Cancer in the Aspect of Environmental Risk from Carcinogens.
    Biomed Res Int. 2017;2017:9643139.
    Abstract    

    Abstract available

  73. KANG HW, Kim YH, Jeong P, Park C, et al
    Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status.
    Oncol Lett. 2017;14:3817-3824.
    Abstract    

    Abstract available

  74. JIANG B, Dong Y, He H, Han C, et al
    Application of pirarubicin photosensitizer fluorescence cystoscopy in early detection of bladder cancer.
    Oncol Lett. 2017;14:3309-3312.
    Abstract    

    Abstract available

  75. HORIKAWA Y, Watanabe M, Sadahira T, Ariyoshi Y, et al
    Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells.
    Oncol Lett. 2017;14:3223-3228.
    Abstract    

    Abstract available

  76. CHRISTOPH F, Konig F, Lebentrau S, Blaschke S, et al
    [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer].
    Aktuelle Urol. 2017 Sep 19. doi: 10.1055/s-0043-109414.
    Abstract    

    Abstract available

  77. STONE L
    Bladder cancer: Shields up, red alert: the blebbishield emergency programme.
    Nat Rev Urol. 2017 Sep 19. doi: 10.1038/nrurol.2017.
    Abstract    



  78. ALIMI Q, Hascoet J, Manunta A, Kammerer-Jacquet SF, et al
    Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder: A systematic review.
    Neurourol Urodyn. 2017 Sep 19. doi: 10.1002/nau.23395.
    Abstract    

    Abstract available

  79. DEKALO S, Matzkin H, Mabjeesh NJ
    Can urologists accurately stage and grade urothelial bladder cancer by assessing endoscopic photographs?
    J Telemed Telecare. 2017 Jan 1:1357633X17727773. doi: 10.1177/1357633X17727773.
    Abstract    

    Abstract available

  80. THOMSEN MBH, Nordentoft I, Lamy P, Vang S, et al
    Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer.
    Sci Rep. 2017;7:11702.
    Abstract    

    Abstract available

  81. JOHN BA, Said N
    Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.
    Oncotarget. 2017;8:57766-57781.
    Abstract    

    Abstract available

  82. KOHLER S, Lee J, George JT, Inzucchi SE, et al
    Bladder cancer in the EMPA-REG OUTCOME trial.
    Diabetologia. 2017 Sep 14. doi: 10.1007/s00125-017-4430.
    Abstract    



  83. LIMA L, Neves M, Oliveira MI, Dieguez L, et al
    Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
    Urol Oncol. 2017 Sep 11. pii: S1078-1439(17)30422.
    Abstract    

    Abstract available

  84. NGUYEN S, Choi C
    Neobladder Stone.
    N Engl J Med. 2017;377:977.
    Abstract    



  85. HAFERTEPE M, Nguyen BD
    Gastrointestinal: Recurrent urothelial cancer of the remnant ureter invading the ileal conduit: PET/CT imaging.
    J Gastroenterol Hepatol. 2017;32:291.
    Abstract    



  86. MATSUSHIMA M, Kikuchi E, Akita H, Miyajima A, et al
    Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy.
    Int J Clin Oncol. 2017;22:554-562.
    Abstract    

    Abstract available

  87. HAN B, Shen Y, Zhang P, Jayabal P, et al
    Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression.
    Oncotarget. 2017;8:22490-22500.
    Abstract    

    Abstract available

  88. TSUDA Y, Nakagawa T, Shinoda Y, Kanatani A, et al
    Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
    Int J Clin Oncol. 2017;22:548-553.
    Abstract    

    Abstract available

  89. CIMPEAN AM, Tarlui V, Cumpanas AA, Bolintineanu S, et al
    Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
    Anticancer Res. 2017;37:4935-4942.
    Abstract    

    Abstract available

  90. MARCHIONI M, Primiceri G, Cindolo L, Hampton LJ, et al
    Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis.
    BJU Int. 2017;120:313-319.
    Abstract    

    Abstract available

  91. BLUTE ML JR, Kucherov V, Rushmer TJ, Damodaran S, et al
    Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.
    BJU Int. 2017;120:387-393.
    Abstract    

    Abstract available

  92. CHAPPIDI MR, Kates M, Tosoian JJ, Johnson MH, et al
    Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.
    BJU Int. 2017;120:377-386.
    Abstract    

    Abstract available

  93. BAILEY GC, Boorjian SA, Ziegelmann MJ, Westerman ME, et al
    Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma.
    BJU Int. 2017;119:585-590.
    Abstract    

    Abstract available

  94. HINATA N, Hussein AA, George S, Trump DL, et al
    Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
    BJU Int. 2017;119:605-611.
    Abstract    

    Abstract available

  95. LI R, Metcalfe MJ, Ferguson Rd JE, Mokkapati S, et al
    Effects of Thiazolidinedione in Patients with Active Bladder Cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14009.
    Abstract    

    Abstract available

  96. VETTERLEIN MW, Gild P, Kluth LA, Seisen T, et al
    Perioperative Allogeneic Blood Transfusion Does Not Adversely Impact Oncological Outcomes After Radical Cystectomy for Urinary Bladder Cancer - a Propensity Score-weighted European Multicenter Study.
    BJU Int. 2017 Sep 14. doi: 10.1111/bju.14012.
    Abstract    

    Abstract available

  97. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    Abstract    

    Abstract available

  98. SCOTT SN, Ostrovnaya I, Lin CM, Bouvier N, et al
    Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin.
    Cancer. 2017;125:416-426.
    Abstract    

    Abstract available

  99. KOPP RP, Stratton KL, Glogowski E, Schrader KA, et al
    Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Cancer. 2017;123:2452-2458.
    Abstract    

    Abstract available

  100. PIATON E, Advenier AS, Carre C, Decaussin-Petrucci M, et al
    p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
    Cancer. 2017;125:552-562.
    Abstract    

    Abstract available

  101. GOLDSTEIN JT, Berger AC, Shih J, Duke FF, et al
    Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer.
    Cancer Res. 2017 Sep 18. pii: canres.1701.2017.
    Abstract    

    Abstract available

  102. WU S, Zheng J, Li Y, Yu H, et al
    A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1510.2017.
    Abstract    

    Abstract available

  103. MARTINEZ VG, Rubio C, Martinez-Fernandez M, Segovia C, et al
    BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1004.2017.
    Abstract    

    Abstract available

  104. MASAOKA H, Matsuo K, Sawada N, Yamaji T, et al
    Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2017 Sep 5. doi: 10.1002/ijc.31028.
    Abstract    

    Abstract available

  105. NARAYAN VM, Adejoro O, Schwartz I, Ziegelmann M, et al
    The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77411-3. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  106. SMITH ZL, Johnson SC, Golan S, McGinnis JR, et al
    Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77409-5. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  107. HURLE R, Lazzeri M, Vanni E, Lughezzani G, et al
    Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project.
    J Urol. 2017 Aug 25. pii: S0022-5347(17)77391-0. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  108. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  109. TSUJITA Y, Horiguchi A, Tasaki S, Isono M, et al
    STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells.
    Oncol Rep. 2017 Aug 11. doi: 10.3892/or.2017.5902.
    Abstract    

    Abstract available

  110. WILLIAMS SB, Huo J, Chu Y, Baillargeon JG, et al
    Cancer and All-Cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-Making.
    Urology. 2017 Aug 25. pii: S0090-4295(17)30886.
    Abstract    

    Abstract available

  111. SCHROECK FR, Patterson OV, Alba PR, Pattison EA, et al
    Development of a Natural Language Processing Engine to Generate Bladder Cancer Pathology Data for Health Services Research.
    Urology. 2017 Sep 12. pii: S0090-4295(17)30966.
    Abstract    

    Abstract available

  112. PARKER WP, Toussi A, Tollefson MK, Frank I, et al
    Risk Factors and Microbial Distribution of Urinary Tract Infections Following Radical Cystectomy.
    Urology. 2016 Apr 25. pii: S0090-4295(16)30114.
    Abstract    

    Abstract available

  113. NEUZILLET Y, Chapeaublanc E, Krucker C, De Koning L, et al
    IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
    BMC Cancer. 2017;17:636.
    Abstract    

    Abstract available

  114. DROOP J, Szarvas T, Schulz WA, Niedworok C, et al
    Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.
    PLoS One. 2017;12:e0176287.
    Abstract    

    Abstract available

  115. HUANG P, Lan M, Peng AF, Yu QF, et al
    Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.
    PLoS One. 2017;12:e0183835.
    Abstract    

    Abstract available

  116. DOWELL AC, Cobby E, Wen K, Devall AJ, et al
    Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.
    PLoS One. 2017;12:e0184841.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;